Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 May 31;7(2):00108-2021.
doi: 10.1183/23120541.00108-2021. eCollection 2021 Apr.

Benefits of pulmonary rehabilitation in COVID-19: a prospective observational cohort study

Affiliations
Comment

Benefits of pulmonary rehabilitation in COVID-19: a prospective observational cohort study

Rainer Gloeckl et al. ERJ Open Res. .

Abstract

Background: Coronavirus disease 2019 (COVID-19) can result in a large variety of chronic health issues such as impaired lung function, reduced exercise performance and diminished quality of life. Our study aimed to investigate the efficacy, feasibility and safety of pulmonary rehabilitation in COVID-19 patients and to compare outcomes between patients with a mild/moderate and a severe/critical course of the disease.

Methods: Patients in the post-acute phase of a mild to critical course of COVID-19 admitted to a comprehensive 3-week inpatient pulmonary rehabilitation programme were included in this prospective, observational cohort study. Several measures of exercise performance (6-min walk distance (6MWD)), lung function (forced vital capacity (FVC)) and quality of life (36-question short-form health survey (SF-36)) were assessed before and after pulmonary rehabilitation.

Results: 50 patients were included in the study (24 with mild/moderate and 26 with severe/critical COVID-19). On admission, patients had a reduced 6MWD (mild: median 509 m, interquartile range (IQR) 426-539 m; severe: 344 m, 244-392 m), an impaired FVC (mild: 80%, 59-91%; severe: 75%, 60-91%) and a low SF-36 mental health score (mild: 49 points, 37-54 points; severe: 39 points, 30-53 points). Patients attended a median (IQR) 100% (94-100%) of all provided pulmonary rehabilitation sessions. At discharge, patients in both subgroups improved in 6MWD (mild/moderate: +48 m, 35-113 m; severe/critical: +124 m, 75-145 m; both p<0.001), FVC (mild/moderate: +7.7%, 1.0-17.8%, p=0.002; severe/critical: +11.3%, 1.0-16.9%, p<0.001) and SF-36 mental component (mild/moderate: +5.6 points, 1.4-9.2 points, p=0.071; severe/critical: +14.4 points, -0.6-24.5, p<0.001). No adverse event was observed.

Conclusion: Our study shows that pulmonary rehabilitation is a feasible, safe and effective therapeutic option in COVID-19 patients independent of disease severity.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: R. Gloeckl has nothing to disclose. Conflict of interest: D. Leitl has nothing to disclose. Conflict of interest: I. Jarosch has nothing to disclose. Conflict of interest: T. Schneeberger has nothing to disclose. Conflict of interest: C. Nell has nothing to disclose. Conflict of interest: N. Stenzel has nothing to disclose. Conflict of interest: C.F. Vogelmeier has nothing to disclose. Conflict of interest: K. Kenn has nothing to disclose. Conflict of interest: A.R. Koczulla has nothing to disclose.

Figures

FIGURE 1
FIGURE 1
Changes in a) 6-min walk distance (6MWD) and b) forced vital capacity (FVC) pre- to post-comprehensive pulmonary rehabilitation (PR) in patients with mild/moderate (n=24) and severe/critical (n=26) coronavirus disease 2019 (COVID-19). c) Development of oxygen saturation (SpO2) during endurance shuttle walk test (ESWT) from baseline to isotime in patients with severe to critical COVID-19 before and after PR. d) Development of breathing rate during ESWT from baseline to isotime in patients with severe to critical COVID-19 before and after PR. Data are presented as median and interquartile range. *: p<0.05, **: p<0.01, ***: p<0.001.

Comment on

References

    1. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team . The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) – China, 2020. China CDC Weekly 2020; 2: 113–122. - PMC - PubMed
    1. World Health Organization . Clinical Management of COVID-19. May 27, 2020. Available from: www.who.int/publications/i/item/clinical-management-of-covid-19 - PubMed
    1. Huang C, Huang L, Wang Y, et al. . 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021; 397: 220–232. doi:10.1016/S0140-6736(20)32656-8 - DOI - PMC - PubMed
    1. Zhou F, Yu T, Du R, et al. . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054–1062. doi:10.1016/S0140-6736(20)30566-3 - DOI - PMC - PubMed
    1. Halpin SJ, McIvor C, Whyatt G, et al. . Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation. J Med Virol 2021; 93: 1013–1022. doi:10.1002/jmv.26368 - DOI - PubMed

LinkOut - more resources